RT Journal Article
T1 Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19
A1 Codina, Helena
A1 Vieitez, Irene
A1 Gutierrez-Valencia, Alicia
A1 Skouridou, Vasso
A1 Martínez, Cristina
A1 Patiño, Lucía
A1 Botero-Gallego, Mariluz
A1 Trujillo-Rodríguez, María
A1 Serna-Gallego, Ana
A1 Muñoz-Muela, Esperanza
A1 Bobillo, María M.
A1 Pérez, Alexandre
A1 Cabrera-Alvar, Jorge Julio
A1 Crespo, Manuel
A1 O'Sullivan, Ciara K.
A1 Ruiz-Mateos, Ezequiel
A1 Poveda, Eva
K1 SARS-CoV-2
K1 Severe COVID-19
K1 Anti-SARS-CoV-2 antibodies
K1 Cytokines
K1 Viral load
K1 COVID-19
K1 Citocinas
K1 Carga viral
K1 Anticuerpos
K1 Diagnosis
K1 Diagnóstico
K1 RNA
AB Viral and host immune kinetics during acute COVID-19 and after remission of acute symptoms need better characterization. SARS-CoV-2 RNA, anti-SARS-CoV-2 IgA, IgM, and IgG antibodies, and proinflammatory cytokines were measured in sequential samples from hospitalized COVID-19 patients during acute infection and six months following diagnosis. Twenty four laboratory confirmed COVID-19 patients with mild/moderate and severe COVID-19 were included. Most were males (83%) with a median age of 61 years. Twenty one percent were admitted to the intensive care unit (ICU) and eight of them (33.3%) met the criteria for severe COVID-19 disease. A delay in SARS-CoV-2 levels' decline during the first six days of follow up, and viral load persistence until month 3 were related to severe COVID-19, but not viral load levels at the diagnosis. Higher levels of anti-SARS-CoV-2 IgA, IgM, IgG and the cytokines IL-6, IL-8 and MIP-1β at the diagnosis time were related to the severe COVID-19 outcome. Higher levels of MIP-1β, IL-1β, MIP-1α and IFN-γ were observed at month 1 and 3 during mild/moderate disease, compared to severe COVID-19. IgG persisted at low levels after six months of diagnosis. In conclusion, higher concentrations of IgA, IgM, and IgG, and IL-6, IL-8 and MIP-1β are identified as early predictors of COVID-19 severity, whereas no significant association is found between baseline SARS-COV-2 viral load and COVID-19 severity.
PB MDPI
YR 2021
FD 2021-10-29
LK http://hdl.handle.net/10668/3885
UL http://hdl.handle.net/10668/3885
LA en
NO Codina H, Vieitez I, Gutierrez-Valencia A, Skouridou V, Martínez C, Patiño L, et al. Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19. Microorganisms. 2021 Oct 29;9(11):2259
DS RISalud
RD Apr 19, 2025